ReviewJournal of inflammation research2026
Atherosclerosis in Rheumatoid Arthritis: The Role of NETs and Management.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA), a chronic inflammatory autoimmune disease, is associated with an increased the risk of cardiovascular disease (CVD), with atherosclerosis as the primary pathological basis. Neutrophil extracellular traps (NETs) represent a plausible pathogenic contributor and biomarker candidate linking RA to accelerated atherosclerosis. This review summarizes the key regulatory factors for the formation of NETs in RA, including autoantibodies, proinflammatory cytokines, cellular crosstalk, post-translational modifications, impaired clearance and neutrophil heterogeneity. Notably, most available supporting evidence is derived from mechanistic studies, preclinical models and associative clinical observations, rather than definitive causal interventional trials. Accumulating evidence suggests that NETs may contribute to RA-associated atherosclerosis via three proposed pathways: endothelial dysfunction, inflammatory plaque progression and instability, and thrombosis. Additionally, this review outlines the multimodal management strategies, encompassing NETs-targeted interventions, RA inflammation control, traditional CVD risk management and biomarker-guided risk stratification. NETs hold promise as a potential therapeutic target to mitigate CVD morbidity and mortality in patients with RA, though further translational and clinical validation is needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.